Inspiration Healthcare Group (IHC)

Sector:

Industrial Chemicals

Index:

FTSE AIM All-Share

31.00p
   
  • Change Today:
    -0.50p
  • 52 Week High: 56.00
  • 52 Week Low: 28.50
  • Currency: UK Pounds
  • Shares Issued: 68.23m
  • Volume: 64,111
  • Market Cap: £21.15m
  • RiskGrade: 227

CureVac rejects reports of White House takeover offer for COVID-19 vaccine

By Alexander Bueso

Date: Wednesday 18 Mar 2020

LONDON (ShareCast) - (Sharecast News) - CureVac has rejected a report at the weekend that the White House had offered to buy out the German-US biotechnology outfit that is developing a possible vaccine for the COVID-19 coronavirus.
In a conference call with journalists, the company did however confirm that it was working with the US Defense Advanced Research Projects Agency and other agencies in America, such as the National Institutes of Health.

It was also in talks with the German government.

But an executive from the company indicated that the report from Welt am Sonntag was not correct, with another saying the firm "did not know" where such information had originated from and therefore could not comment on the reports.

The newspaper, which cited an anonymous source within the German government, said that the White House was pushing for exclusive access to the supply of the vaccine.

CureVac also said it had received no such approach, although it did not know if other conversations might have taken place in the background that it was unaware of.

Two senior American officials had told the New York Times on Sunday that some of the German news accounts first reporting the story were overblown, particularly with regards to any effort by the United States "to secure exclusive access to a vaccine".

And one German official told the NYT it was not clear if the US was just seeking access to the coronavirus research and for production to be conducted on American soil.

A Coronavirus vaccine may be possible by autumn

On Tuesday evening, European Commission chief, Ursula Von der Leyen, said that the European Commission would do everything in its power to try and develop a vaccine by autumn 2020.

Typically, experts say that a normal timeline for developing a vaccine is more on the order of a year or a year and a half.

Von der Leyen, however, believed that timeline could potentially be reduced in half or two-thirds by accelerating the bureaucratic processes involved, AFP reported.

She referred specifically to a company "that other countries want to buy out, meaning that it is the leader", reportedly adding that the company believed that it might be possible to develop the vaccine by autumn.





Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

IHC Market Data

Currency UK Pounds
Share Price 31.00p
Change Today -0.50p
% Change -1.59 %
52 Week High 56.00
52 Week Low 28.50
Volume 64,111
Shares Issued 68.23m
Market Cap £21.15m
RiskGrade 227

IHC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
81.64% above the market average81.64% above the market average81.64% above the market average81.64% above the market average81.64% above the market average
76.47% above the sector average76.47% above the sector average76.47% above the sector average76.47% above the sector average76.47% above the sector average
Price Trend
74.02% below the market average74.02% below the market average74.02% below the market average74.02% below the market average74.02% below the market average
Sector averageSector averageSector averageSector averageSector average
Income
30.33% above the market average30.33% above the market average30.33% above the market average30.33% above the market average30.33% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Growth
81.11% below the market average81.11% below the market average81.11% below the market average81.11% below the market average81.11% below the market average
77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

IHC Dividends

  Latest Previous
  Interim Final
Ex-Div 23-Nov-23 29-Jun-23
Paid 22-Dec-23 28-Jul-23
Amount 0.20p 0.41p

Trades for 29-Apr-2024

Time Volume / Share Price
15:46 4,000 @ 30.06p
15:37 1 @ 30.00p
12:17 15,000 @ 30.50p
12:16 20,000 @ 30.50p
12:11 1,141 @ 31.02p

IHC Key Personnel

CEO Neil Campbell
COO Brook Nolson
CFO Alan Olby

Top of Page